Ronald Chen, MD, MPH

Associate Professor; Radiation Oncology Residency Program Director; Associate Chair for Education

Ronald Chen


Phone: (984) 974-0400                                                                                       
Fax: (984) 974-8607


Prostate Cancer


MD Harvard Medical School, Boston, MA (2004) 

Residency - Harvard Radiation Oncology Program, Boston, MA (2005-2009) 

MPH Harvard School of Public Health, Boston, MA (2008)

BA University of Kansas, Lawrence, KS

Board Certifications

American Board of Radiology Focused Practice Recognition in Brachytherapy (lifelong recognition) (2015)
ABR Board Certified in Radiation Oncology (2010)

North Carolina (2009)
Commonwealth of Massachusetts (2006)

Academic Honors and Awards

2017   UNC Health Care and Faculty Physicians Carolina Care Excellence  Leader

2016    ASCO Advocacy Champion

2016   Carolina Care Excellence Award

2014   UNC Alpha Omega Alpha (AOA) Faculty Member inductee

2013   UNC James W. Woods Junior Faculty Development Award

2013   Association of Residents in Radiation Oncology (ARRO) Educator of the Year

2013   Inducted as Member of UNC School of Medicine Academy of Educators

2012   UNC School of Medicine Academy of Educators Medical Student Research Mentor Award

2011   Department of Radiation Oncology Excellence in Teaching Award

2010   University of North Carolina Junior Faculty Development Award

2009   ASCO/AACR Methods in Clinical Research (Vail Workshop)

2009   ASCO Cancer Foundation Merit Award

2008   Radiation Therapy Oncology Group (RTOG) Meeting Travel Grant

2007   CaPSURE Scholar: UCSF Cancer of the Prostate Strategic Urologic Research Endeavor

2006   Travel grant, American Society for Therapeutic Radiology and Oncology Health Services/Outcomes Research in Oncology Symposium

2004   Cum laude (Harvard Medical School)

2001   Doris Duke Clinical Research Fellow

2001   Leopold Schepp Foundation Scholarship

2000   Harvard Medical School PASTEUR Fellow – Patient-Associated Science: Training, Education, Understanding, and Research

1999   Highest Distinction (equivalent to summa cum laude), University of Kansas

1996   Barry M. Goldwater Scholar

Grants (Active)

  1. 1R01CA174433-01 PROMIS validation in prospective population-based prostate cancer research study. Principal Investigator. (2012-2016 no cost extension).

  2. A Survivorship Action Partnership – USA (Movember Foundation, LIVEStrong Foundation). This is a consortium of 15 institutions across the US selected to design and implement interventions to improve prostate cancer survivorship. Prinicpal Investigator (UNC); Co-lead (Survivorship Care Plan Team). (2014-2018).

  3. 1R01EB020426-01. SCH: Proactive health monitoring using individualized analysis of tissue elasticity. Principal Investigator. (2014-2017).

  4. CER-1310-06453 (Patient-Centered Outcomes Research Institute/PCORI) North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS): A Stakeholder-Driven, Population-Based Prospective Cohort Study. Principal Investigator (2015-2018).

  5. CER-1503-29220 (Patient-Centered Outcomes Research Institute/PCORI) Optimizing the effectiveness of routine post-treatment surveillance in prostate cancer survivors. Principal Investigator. (2015-2018).

  6. 1R21CA212516-01. Using SCP to tailor and deliver a prostate cancer symptom management program. Co-investigator. (2016-2018). 

Clinical Trials (Active)

  1. IRB #14-0374 (LCCC #1408) Investigation of Circulating Tumor Cells from Cancer Patients Undergoing Radiation Therapy. Principal Investigator.
  2. IRB #16-2873 (LCCC #1636) Using PROMIS as part of routine clinical care for racially diverse prostate and bladder cancer patients. Principal Investigator.


  1. Kim SI, Swanson TA, Chen RC, editors. Underground Clinical Vignettes: Ob/Gyn, Classical Clinical Cases for USMLE Step 2 and Clerkship Review, 4th Edition. Lippincott Williams & Wilkins, New York, NY. [ISBN-10: 0781768403] 
  2. Chen RC, Section Editor. [A. Tewari, editor] Prostate Cancer: a Comprehensive Perspective, 1st Edition. Springer, New York, NY. 2011. [ISBN-10: 144712863X]

Book Chapters

  1. Chen RC, Mauch PM. [Specht and Yahalom, editors] Management of Lymphocyte-Predominant Hodgkin Lymphoma. Radiotherapy for Hodgkin Lymphoma. Springer, New York, NY. 2010. [ISBN-10: 3540784551
  2. Chen RC, Holmes JA, D’Amico AV. Duration of Neoadjuvant/Adjuvant Androgen-Deprivation Therapy in Non-Metastatic Prostate Cancer. Radiation Medicine Rounds 2:1 (2011) 43-58. Demos Medical Publishing LLC. New York, NY. [ISBN-10: 1936287331]
  3. Meyer J, Holmes JA, Chen RC. [A. Tewari, Editor] Proton beam therapy and novel radiotherapeutic approaches. Prostate Cancer: a Comprehensive Perspective, 1st Edition. Springer, New York, NY. 2013. [ISBN-10: 144712863X]
  4. Holmes JA, Chen RC. [A. Tewari, Editor] Radiotherapy plus hormonal therapy. Prostate Cancer: a Comprehensive Perspective, 1st Edition. Springer, New York, NY. 2013. [ISBN-10: 144712863X]
  5. Smith A, Balar AV, Milowsky MI, Chen RC. [Niederhuber, Armitage, Doroshow, Kastan, Tepper, Editors] Bladder cancer. Abeloff’s Clinical Oncology, 5th Edition. Elsevier. [ISBN: 978-1-4557-2865-7]
  6. D’Amico AV, Nguyen P, Crook JM, Chen RC, Koontz BF, Martin N, Lee WR, DeWeese TL. [Wein, Kavoussi, Partin, Peters, Editors] Radiation therapy for prostate cancer. Wein: Campbell-Walsh Urology, 11th Edition. Elsevier.
  7. Baker BR, Mohiuddin JJ, Chen RC. Radiation with hormonal therapy. Prostate Cancer, 2nd Edition. Elsevier.
  8. Chen RC, Broughman JR, Michalski JM. Quality, value and the assessment of new technology. Quality and Safety in Radiation Oncology